Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.


In thousands of US dollars ($)	Year Ended December 31, 2021
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
Product Sales - Point-in-time	$	835	$	835	$	—
License Fee – Over time	241		—		241
Total Drug Products	1,076		835		241
Concentrate Products
Product Sales – Point-in-time	58,913		52,614		6,299
License Fee – Point-in-time	1,942		1,942		—
Total Concentrate Products	60,855		54,556		6,299
Net Revenue	$	61,931	$	55,391	$	6,540

In thousands of US dollars ($)	Year Ended December 31, 2020
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
Product Sales - Point-in-time	$	910	$	910	$	—
License Fee – Over time	226		—		226
Total Drug Products	1,136		$	910	226
Concentrate Products
Product Sales – Point-in-time	59,100		53,707		5,393
License Fee – Point-in-time	1,961		1,961		—
Total Concentrate Products	61,061		55,668		5,393
Net Revenue	$	62,197	$	56,578	$	5,619

Contract balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.


In thousands of US dollars ($)	December 31, 2021		December 31, 2020
Receivables, which are included in "Trade and other receivables"	$	5,913	$	4,171
Contract liabilities	$	8,157	$	10,190

Summary of potentially dilutive securities

Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the years ended December 31, 2021 and 2020 were as follows:


	As of December 31,
	2021	2020
Options to purchase common stock	5,814,506	6,467,956
Unvested restricted stock awards	78,300	146,800
Unvested restricted stock units	322,182	265,494
Warrants to purchase common stock	26,426,863	26,426,863
Total	32,641,851	33,307,113